{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:40:42Z","timestamp":1790685642531,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.nucmedbio.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T06:33:57Z","timestamp":1549780437000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Comparative evaluation of [18F]DiFA and its analogs as novel hypoxia positron emission tomography and [18F]FMISO as the standard"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7662-3755","authenticated-orcid":false,"given":"Norihito","family":"Nakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kiriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-4750","authenticated-orcid":false,"given":"Yuki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagara","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0167-8140(00)00223-1","article-title":"A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy","volume":"57","author":"Nordsmark","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clon.2014.02.002","article-title":"The meaning, measurement and modification of hypoxia in the laboratory and the clinic","volume":"26","author":"Hammond","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/3579620","article-title":"Cells at intermediate oxygen levels can be more important than the \u201chypoxic fraction\u201d in determining tumor response to fractionated radiotherapy","volume":"147","author":"Wouters","year":"1997","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/bjc.2014.610","article-title":"Imaging tumour hypoxia with positron emission tomography","volume":"112","author":"Fleming","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0025","first-page":"365","article-title":"PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence","volume":"4","author":"Lopci","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0030","article-title":"Imaging mass spectrometry revealed the accumulation characteristics of the 2-nitroimidazole-based agent \u201cpimonidazole\u201d in hypoxia","volume":"5","author":"Masaki","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0035","article-title":"The accumulation mechanism of the hypoxia imaging probe \u201cFMISO\u201d by imaging mass spectrometry: possible involvement of low-molecular metabolites","volume":"11","author":"Masaki","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00259-005-1951-4","article-title":"NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours","volume":"33","author":"Wyss","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0045","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1158\/1078-0432.CCR-05-1773","article-title":"Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer","volume":"12","author":"Rajendran","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0050","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1007\/s00259-014-2776-9","article-title":"Correlation between 18F-fluoromisonidazole PET and expression of HIF-1\u03b1 and VEGF in newly diagnosed and recurrent malignant gliomas","volume":"41","author":"Kawai","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2012.08.019","article-title":"Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer","volume":"105","author":"Zips","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.radonc.2011.07.029","article-title":"Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance","volume":"101","author":"Hendrickson","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.112.109330","article-title":"High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer","volume":"54","author":"Okamoto","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1099-1344(199901)42:1<3::AID-JLCR160>3.0.CO;2-H","article-title":"Fluoroazomycin arabinoside (FAZA): synthesis, H-2 and H-3-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia","volume":"42","author":"Kumar","year":"1999","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0969-8051(02)00442-0","article-title":"[18F]-Fluoroazomycin arabinofuranoside (18FAZA) and [18F]-Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumours","volume":"30","author":"Sorger","year":"2003","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2012.04.011","article-title":"Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry","volume":"105","author":"Tran","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0085","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00259-009-1154-5","article-title":"Initial results of hypoxia imaging using 1-a\u2032-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)","volume":"36","author":"Postema","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0090","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/MNM.0b013e3283407950","article-title":"Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET\/CT","volume":"31","author":"Doss","year":"2010","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0095","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1073\/pnas.1102526108","article-title":"Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging","volume":"108","author":"Dubois","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.radonc.2013.08.031","article-title":"Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters","volume":"109","author":"Zegers","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0105","first-page":"106","article-title":"Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside","volume":"46","author":"Piert","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1148\/radiology.194.3.7862981","article-title":"Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia","volume":"194","author":"Yang","year":"1995","journal-title":"Radiology"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0115","first-page":"1523","article-title":"Evaluation of a new PET hypoxia probe, [18F]HIC101, in comparison with [18F]FMISO","volume":"53","author":"Nakata","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0120","first-page":"235","article-title":"Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution","volume":"27","author":"Hamacher","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2307\/3575246","article-title":"Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole","volume":"82","author":"Brown","year":"1980","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/0008-5472.CAN-03-2424","article-title":"Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding","volume":"64","author":"Evans","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0135","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ijrobp.2005.05.068","article-title":"EF5 binding and clinical outcome in human soft tissue sarcomas","volume":"64","author":"Evans","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0140","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2967\/jnumed.108.053785","article-title":"F-18-EF5: a new PET tracer for imaging hypoxia in head and neck cancer","volume":"49","author":"Komar","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2014.09.045","article-title":"A comparative study of the hypoxia PET tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a preclinical tumor model","volume":"91","author":"Peeters","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0150","first-page":"1397","article-title":"Pharmacokinetics of [18F]FETNIM: a potential marker for PET","volume":"42","author":"Gr\u00f6nroos","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0360-3016(92)91001-4","article-title":"Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole","volume":"22","author":"Koh","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2019.01.008_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2012.04.011","article-title":"Hypoxia imaging with the nitroimidazole 18F-FAZA PET probe: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry","volume":"105","author":"Tran","year":"2012","journal-title":"Radiother Oncol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511830324X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511830324X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:28:13Z","timestamp":1760848093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511830324X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":32,"alternative-id":["S096980511830324X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.01.008","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative evaluation of [18F]DiFA and its analogs as novel hypoxia positron emission tomography and [18F]FMISO as the standard","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}